Vanda Pharmaceuticals (VNDA) Cost of Revenue (2010 - 2026)

Vanda Pharmaceuticals has reported Cost of Revenue for 14 years, with the latest figure at $3.2 million in Q1 2026.

• Quarterly Cost of Revenue fell 10.28% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 million (up 11.29% YoY) and the FY2025 annual result came in at $13.0 million, up 15.29% from the prior year.
• Cost of Revenue slipped to $3.2 million in Q1 2026 per VNDA's latest filing, from $3.8 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $6.3 million in Q3 2022 and troughed at $2.6 million in Q3 2024.
• A 5-year average of $3.9 million and a median of $3.5 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue tumbled 51.53% in 2023, then jumped 47.99% in 2025.
• Over 5 years, Cost of Revenue stood at $6.2 million in 2022, then slumped by 44.53% to $3.5 million in 2023, then decreased by 25.14% to $2.6 million in 2024, then surged by 47.99% to $3.8 million in 2025, then retreated by 17.58% to $3.2 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.2 million, $3.8 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.